All News
EULAR 2025 - Day 1 Report
Wednesday was Day One at EULAR 2025 in Barcelona. Thousands from around the world gathered, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1.
Read Article
T2T in #gout w serum #uric #acid / #urate target
SAVES LIVES
Study of achievement of target 🎯
⬇️CVE and death
If not achieving Urate <360
T2T also reduced baseline #SUA
#EULAR2025 @rheumnow abst#OP0005 https://t.co/ePchJ4vqnU
Janet Pope Janetbirdope ( View Tweet)
Secukinumab for PMR?
-post hoc analysis of the TitAIN study (phase 2 RCT on new onset/relapsing GCA) showed:
-Numerical reduction in patients experiencing PMR symptoms when treated with secukinumab compared to placebo.
-Safety profile was similar to the overall GCA study
Adela Castro AdelaCastro222 ( View Tweet)
SPEED RCT: In early PsA with poor prognostic factors, PASDAS at 24wks:
•Early TNFi: 3.7
•Combo csDMARDs: 4.1
•Step-up csDMARDs: 4.7
Early TNFi beat step-up by -1.09 (p<0.001); combo csDMARDs also superior (-0.69, p=0.02). Early TNFi benefit sustained at 48wks. Abstract#OP0089 https://t.co/MpazF8BIr2
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
In vitro, balinatunfib (TNFR1-selective inhibitor) preserved Treg expansion in CD4+ T cells co-cultured with IL-2 and memTNF (Treg 8.99 percent, p<0.0001), unlike adalimumab and etanercept which reduced Tregs by 27.5 to 41 percent. Confirms TNFR2 sparing with selective TNFR1 https://t.co/xaczz87Xrd
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#EULAR2025 Abstr#OP0002 Promising new mode of action therapy for #myositis. Phase 2 RCT of efgartigimod (FcRn-i; coformulated with recombinant PH20) showed improvement in TIS & other key endpoints vs PBO at Wk24. Injection reaction common (23%). Will proceed to Phase 3 @RheumNow https://t.co/SuMolfcDkS
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Phase 3 of POETYK-PsA-2:
-Deucravacitinib (oral TyK2i) met the primary endpoint of ACR20 at week 16 and was superior to placebo in multiple PsA domains.
-Clinical efficacy maintained until week 52.
-No major safety signals reported.
-Notably high placebo response rates.
Abstract
Adela Castro AdelaCastro222 ( View Tweet)
📊 In a 40-yr cohort (n=2818), RA pts had 2.3x ↑ risk of DVT (HR 2.26) & 1.6x ↑ risk of PE (HR 1.61) vs non-RA.
Risk ↑ with RF/CCP+, nodules (HR 2.9), BMI ≥30 (HR 1.9), & biologic use in year 1 (HR 2.4–2.9).
Remission = ↓ PE risk (HR 0.47)
đź“ŤOP0070
@RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
POS0627: RA patients aged ≥90 yrs can benefit from biologics/JAKi! In 3,600 pts, 84% of those ≥90 achieved low disease activity, 71% were on JAKi. But serious infections occurred in 21%—mostly pneumonia. Use w/caution in the oldest-old. #EULAR2025 @rheumnow
Jiha Lee JihaRheum ( View Tweet)
❓️How effective and safe is it to combine bDMARDs and tsDMARDS (i.e. TNFi/ IL17i + JAKi/TYKi) in #psoriatic_arthritis?
🅰️ Reassuring data from a case-series study presented by Andre Lucas Ribeiro
#EULAR2025
OP0090
@RheumNow
#Strategy https://t.co/W8fuzSgxbJ
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Ph 2 RCT Sonelokimab (IL-17A- & IL-17F-inhibiting Nanobody) 24wks
207 pts SON 120 MDA 51% vs. 45% ADA
Subgroups: female 52%, weight ≥100kg 53%, ≥3% BSA 55%
Composite ACR70/PASI100 SON 120 48% vs. 19% ADA
No new safety signal
Ph 3 on the way 2 doses SON 60 &120
#OP0096 https://t.co/w5QtpKbi1W
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Efficacy and safety of deucravacitinib up to week 52 in the POETYK PsA-2 study
•ACR20 at W16: 54.2% (deucravacitinib) vs 39.4% (placebo), p=0.0002
•PASI75: 40.9% vs 15.4%, p<0.0001
•MDA: 25.6% vs 14.7%, p=0.0007
•FACIT-F: +2.5 vs +1.8
•SAE: 1.9% (low)
TYK2 inhibition shows https://t.co/JXTZRk2itA
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#EULAR2025 Abstr#OP0078 #Lupus nephritis is assoc with CVD. Propensity matched analysis comparing GLP-1 agonist vs SLGT2-i using TrinetX database in LN ->favourable risk reduction with GLP-1:
-CKD progression
-Mortality
-MI
Validation & mechanistic explanation needed @RheumNow https://t.co/xPDVDm1CHm
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
In propensity-matched RA cohort (n=2,449 each) on JAK inhibitors, adding a GLP-1 agonist reduced risk of: • Acute coronary syndromes (RR 0.65, p=0.0009) • DVT (RR 0.69, p=0.007) Overall CV events ↓ by 33% (RR 0.67, p=0.0007)
#EULAR2025 @RheumNow
Abstract#OP0069 https://t.co/jWI6tvri8O
Jiha Lee JihaRheum ( View Tweet)
Can RA be intercepted?
In the ALTO follow-up of the APIPPRA RCT (Cope et al), 1 year of abatacept delayed RA onset by up to 3 years in ACPA+/RF+ individuals. Effect strongest in those with mature autoantibody profiles.
Abstract#OP0004
@RheumNow #EULAR2025 https://t.co/N7YwtYod8w
Jiha Lee JihaRheum ( View Tweet)
RA pts have ↑ risk of DVT (HR 2.26) & PE (HR 1.61) vs controls in this 40-year, pop-based study. Nodules, obesity, high disease activity & early biologic use ↑ risk. Remission in year 1 halved PE risk. VTE risk persists despite therapeutic advances.
@RheumNow #EULAR2025 #OP0070 https://t.co/AaBi2o2cUw
Mrinalini Dey DrMiniDey ( View Tweet)
MONITOR PsA 200+ pts secondary care "real-life" cohort
65 treated w/ combi csDMARDs
48weeks outcome and 96 weeks
49% bioDMARDs, 29% retention and 23% deescalation to 1 csDMARD
‼️reasons for discontinuation was AEs in 60% cases not inefficacy
Caveat: analysis not adjusted for https://t.co/L8EczgZTpP
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Clinical determinants of multiple drug failure in D2T RA
2000+ RA cohort 250+ refractory
-Low financial status
-Cancer Hx
-CV comorbidities
-Chronic use of NSAID or GCs
Protective: Regular participation in leisure activities
#POS0030 @RheumNow #EULAR2025 https://t.co/qNHQoHCb80
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
If you successfully taper off DMARDs in RA patients in remission, do you risk bringing new joints in the mix?
Leiden post-hoc trial: these patients don’t do worse than those who never get off drug.
Drug-free remission tricky but new joints not a worry. #EULAR2025 @RheumNow https://t.co/QDxNRPN9f1
David Liew drdavidliew ( View Tweet)
🎩REGENCY: Obinutuzumab + standard therapy improved renal outcomes in #lupus nephritis across all tested response definitions (REGENCY, BLISS-LN, AURORA-1). Week 76 CRR consistently 13–16% higher vs placebo. Results hold despite variable thresholds.
@RheumNow #EULAR2025 #OP0006
Mrinalini Dey DrMiniDey ( View Tweet)
